Semiannual Report — FY2026 H1
What ZERIA PHARMACEUTICAL CO.,LTD. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-06View the original on EDINET
How much it says
66Detailed
What moved here
11named for the first time
Its own wording
21terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
The company disclosed an analysis of its business results and financial position for the current interim consolidated accounting period, together with interim consolidated financial statements. It also entered into an equity transfer agreement dated 23 October 2026 with Tillotts Pharma AG for the acquisition of all equity interests in Haupt Pharma Wülfling GmbH. The business combination date is scheduled for January 2027 or later.
Komori's summary of this document, not the document's own words.66Detailed
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
61
Detailed
90
Very detailed
75
Very detailed
68
Detailed
37
Thin
62
Detailed
60
Detailed
55
Typical
73
Detailed
R&D spend2百万円Money spent making new things.
Cash left over4百万円Cash from the business, less what went into equipment.
Spent on equipment1百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.